## Abbreviations  
AChEacetylcholinesteraseeraseADAlzheimer's diseaseAPPamyloid precursor proteinBChE, BuChEbbutyrylcholinesteraseeraseBFCAb bifunctional coupling agentCN-BPCA succinimidyl! isocyanobutyricc esterCNScentral nervous systemDOTA1,4,7,10-tetrazacyclododecane-1,4,7,10-tetraacetic acidDOTAGA-Bn-NCS2,2,2,2,2,2,2,2,2,2,2,-(10-(1-carboxy-4-((4-isothiocyanatopbenzyl)amino)-4-oxobutyl)-1,4,7,10-tetrazacyclododecane-1,4,7-triyl)triacetic acidDTPA-CHX-Bn-NCS [(R)-2-Amino-3-(4-isothiocyanatophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acidFDAUS Food and Drug AdministrationHYNIC6-hydroxazinicotinamideINintransalIRinfraredspectrumIV intravenousMRImagnetic resonance imagingMSmass spectrumMTHA, N-methyl-THANMR1,2,3,4-tetrahydro-9-methyl-amino acidineNMRnuclear magnetic resonanceNODAGA-Bn-NCS2  
* _[PERSON] et al. (2021)_ [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. _Sci. Transl. Med._**2021**, _13_, eaaz4564. [CrossRef] [PubMed]
* _[PERSON] et al. (2020)_ [PERSON]; [PERSON] [PERSON]; [PERSON] Familial Alzheimer's disease mutations at position 22 of the amyloid \(\beta\)-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system. _PLoS ONE_**2020**, _15_, e0239584. [CrossRef] [PubMed]
* _[PERSON] et al. (2022)_ [PERSON]; [PERSON]; [PERSON]; [PERSON] Role of Cholinergic Signaling in Alzheimer's Disease. _Molecules_**2022**, _27_, 1816. [CrossRef] [PubMed]
* [PERSON] (1999) [PERSON]; [PERSON]; [PERSON] [PERSON] The cholinergic hypothesis of [PERSON]'s disease: A review of progress. _J. Neurol. Neurosurg. Psychiatry_**1999**, _66_, 137-147. [CrossRef] [PubMed]
* _[PERSON] et al. (2002)_ [PERSON]; [PERSON] Cholinergic drugs in pharmacotherapy of Alzheimer's disease. _Mini Rev. Med. Chem._**2002**, \(2\), 11-25. [CrossRef]
* [PERSON] et al. (2016) [PERSON]; [PERSON]; [PERSON]; [PERSON] Alzheimer's disease: Targeting the Cholinergic System. _Curr. Neuropharmacol._**2016**, _14_, 101-115. [CrossRef]
* _[PERSON] et al. (2013)_ [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Acetylcholinesteraseerase inhibitors: Pharmacology and toxicology. _Curr. Neuropharmacol._**2013**, _11_, 315-335. [CrossRef] [PubMed]
* _[PERSON] et al. (2021)_ [PERSON]; [PERSON] Acetylcholinesteraseerase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesteraseerase in their Pathogenesis. _Int. J. Mol. Sci._**2021**, _22_, 9290. [CrossRef]
* _[PERSON] et al. (2021)_ [PERSON]; [PERSON]; [PERSON]; [PERSON] Adverse Drug Reactions of Acetylcholinesteraseerase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review. _Ther. Clin. Risk Manag._**2021**, _17_, 927-949. [CrossRef] [PubMed]
* _[PERSON] et al. (2002)_ [PERSON]; [PERSON]; [PERSON] Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. _Clin. Pharmacokinet._**2002**, _41_, 719-739. [CrossRef]
* _[PERSON] (1994)_ [PERSON] Tacrine: First drug approved for Alzheimer's disease. _Ann. Pharmacother._**1994**, _28_, 744-751. [CrossRef] [PubMed]
* _[PERSON] et al. (1995)_ [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON] Tetrahydroaminoacridine modulates technetium-99m labelled ethylene diccysteine retention in Alzheimer's disease measured with single photon emission computed tomography imaging. _Neurosci. Lett._**1995**, _195_, 53-56. [CrossRef]
* _[PERSON] et al. (2020)_ [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement. _Biomolecules_**2020**, _10_, 40. [CrossRef]
* _[PERSON] (2002)_ [PERSON]; [PERSON] Use of cholinesterase inhibitors in dementia. _Adv. Psychiatr. Treat._**2002**, \(8\), 89-96. [CrossRef]
* _[PERSON] (2009)_ [PERSON]; [PERSON] Side Effects of Approved Antidetermatives. _Psychiatr. Daupl._**2009**, _21_, 108-113. * _[PERSON] et al.